Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

NCT05537571 is registered in ClinicalTrials.gov with Silence Therapeutics plc as lead sponsor.

NCT NCT05537571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Lead sponsor
Silence Therapeutics plc
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2022
Completion date
July 1, 2024
Enrollment
180 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, cardiovascular diseases, lipoprotein(a)